Literature DB >> 2018345

O6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukemia.

M D'Incalci1, P Taverna, E Erba, S Filippeschi, D Potenza, L Mariani, L Citti, C V Catapano.   

Abstract

Using L1210 and a subline resistance to chloroethylnitrosoureas (L1210/BCNU), we found that the resistance to 1-(2-chloroethyl)-1-nitrosourea (CNU) or to diethyl-1-3-(2-chloroethyl)-3-nitrosoureido ethyl phosphonate (fotemustine) can be reversed by a pretreatment with O6-methyl Guanine (O6-mGua) or temozolomide. In L1210/BCNU but not in L1210 the pretreatment with O6mGua caused an increased peak level of CNU-induced DNA-interstrand crosslinks. We then evaluated whether the resistance to BCNU could be counteracted in vivo by i.p. O6mGua treatment of L1210/BCNU bearing mice. The results were negative due to the fact that O6mGua, which was not toxic when given alone, caused a high toxicity when associated with BCNU.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2018345

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.

Authors:  Jeffrey J Raizer; Mark G Malkin; Martin Kleber; Lauren E Abrey
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

2.  Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  R B Mitchell; M E Dolan
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study.

Authors:  Michele Guida; Antonio Cramarossa; Ettore Fistola; Mariangela Porcelli; Giuseppe Giudice; Katia Lubello; Giuseppe Colucci
Journal:  J Transl Med       Date:  2010-11-10       Impact factor: 5.531

4.  Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.

Authors:  S R Wedge; J K Porteus; B L May; E S Newlands
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

5.  Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.

Authors:  E S Newlands; T Foster; S Zaknoen
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.